BRIM is a virtually operating company established in 2013 in Taipei, Taiwan, focusing on developing new drugs in various areas, including oncology and infectious disease. BRIM’s pipeline is generated from sourcing deals both within and outside of Taiwan, with its experienced team surveying many small molecules, peptides, biologics, and platform technologies at the lead optimization stage.  Projects are brought into BRIM through co-development partnerships or in-licensing deals, and development of the projects is conducted at global CROs and CMOs that fit the needs of the project.  Once clinical proof of concept (POC) is reached, the projects are partnered out for further clinical development.